Advancing the Standard: How the PCCTC Led the Science at the 2026 ASCO GU Symposium and Forged New Paths for Collaboration www.linkedin.com/pulse/advanc...

PCCTC SOC Chair and PCWG4 Co-Lead Author @mjmorrismd.bsky.social discusses Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4 with @oncoalert.bsky.social www.linkedin.com/feed/update/...

‼️#GU26 simultaneous publication by @AarmstrongDuke et al:  Trial Design and Objectives for Patients with Prostate Cancer: Recommendations From Prostate Cancer Working Group 4 Learn more: https://bit.ly/46dupmq

PCCTC investigator and PCWG4 co-lead author Dr Andrew J. Armstrong discusses the new prostate cancer trial design recommendations with OncoAlert: www.linkedin.com/feed/update/...

Just published! Prostate Cancer Working Group 4 recommendations are now available in the Journal of Clinical Oncology, providing updated standards for clinical trial design, patient eligibility, and outcome measures in advanced prostate cancer: ascopubs.org/doi/pdfdirec...

We’re excited to highlight the groundbreaking research being shared tomorrow by PCCTC investigators at #GU26! From cutting-edge clinical trial results to revised PCWG4 guidelines, these abstracts showcase the passion and progress driving the future of prostate cancer care.

K36 Therapeutics Highlights PCCTC-managed First-in-Human KTX-2001 Prostate Cancer Study Design at #GU26 www.prnewswire.com/news-release...

Prostate Cancer Working Group 4: What Does Its Work Mean for the Busy Clinician? #ASCODailyNews speaks with PCCTC investigators Drs Michael Morris and Andrew Armstrong: dailynews.ascopubs.org/do/prostate-...

PCCTC Investigator Dr. Maha Hussain to Present BRCAAway Prostate Cancer Trial Results at #GU26 Showing Median Survival Exceeding 5 Years with Abiraterone Plus Olaparib www.pcctc.org/news/landmar...

We are pleased to announce the first public presentation of updated global standards for advanced prostate cancer clinical trials, Prostate Cancer Working Group 4 (PCWG4), at #GU26: www.pcctc.org/news/prostat...

PCCTC Investigators To Showcase Groundbreaking Prostate Cancer Research at 2026 ASCO GU Symposium (#GU26): www.pcctc.org/news/pcctc-i...

The Uromigos podcast delves into the evolution and significance of the Prostate Cancer Working Group Criteria (#PCWG4) with guests PCCTC SOC chair @mjmorrismd.bsky.social and PCCTC investigator Dr Andrew Armstrong: creators.spotify.com/pod/profile/...

K36 Therapeutics Completes Dosing of First Cohort in PCCTC-Managed Phase 1 Clinical Trial of NSD2 Inhibitor KTX-2001 in Prostate Cancer www.prnewswire.com/news-release...

PCCTC investigators Drs. Mary-Ellen Taplin and Andrew Armstrong discuss ASCO's first living guidelines for prostate cancer: www.oncologynewscentral.com/prostate-can...

In an effort by PCCTC investigators and colleagues, the importance of racial diversity in future genomic profiling and clinical trials efforts is highlighted. Full manuscript: pmc.ncbi.nlm.nih.gov/articles/PMC...

PCCTC investigator @dangeorgemd.bsky.social of Duke University discusses the role of radioligand therapy in prostate cancer management: www.onclive.com/view/dr-geor...

The PCCTC plans on hiring three summer interns to support our Data Management, Data Science, and Clinical Operations teams. The 10-week internships are full-time, paid, 100% remote, and working hours are 9-5 EST. To learn more visit www.pcctc.org/news/2026-su...

Prostate Cancer Clinical Trials Consortium (PCCTC) Innovation Featured at Biocom California’s “Innovations in Oncology Clinical Trial Design” Forum www.linkedin.com/pulse/prosta...

Just published - DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis www.nature.com/articles/s41...

The PCCTC's phase 2 study of talazoparib with or without enzalutamide in patients With metastatic castration-resistant prostate cancer and HRR mutations after progression on abiraterone acetate (TALENT) is now actively enrolling. To learn more visit clinicaltrials.gov/study/NCT068...

The first site for the first-in-human KTX-2001 STRIKE-001 prostate cancer study has been activated at USA Clinical Trials (San Antonio, TX)—setting a PCCTC benchmark from reg packet distribution to site initiation. www.linkedin.com/posts/k36-th...

We are proud to collaborate with the Latin American Cooperative Oncology Group (LACOG) on innovative multicenter clinical studies like DORA and the IRONMAN Registry www.linkedin.com/embed/feed/u...

PCCTC investigators publish results from the phase 1b DeLLpro-300 study of tarlatamab in patients with neuroendocrine prostate cancer: aacrjournals.org/clincancerre...

Prognostic Significance of PSA>0.2 After 6-12 Months Treatment for mHSPC Intensified by ARPI: A Multinational Real-World Analysis of the IRONMAN Registry. Story via UroToday: www.urotoday.com/conference-h...

PCCTC investigator Rana McKay, MD, outlines key findings from the phase 2 COMRADE trial via Urology Times www.urologytimes.com/view/rana-mc...

Consensus Guidelines Needed to Further Optimize PARP Inhibition, Molecular Imaging, and ARPI Use in Prostate Cancer Management @ucsdhealth.bsky.social #ProstateCancer #PCSM www.onclive.com/view/consens...

Such an honor and so much fun to join the Cancer Clear and Simple @uwhealth.bsky.social Carbone Cancer Center Podcast to discuss liquid biopsies in cancer! cancer.wisc.edu/community-ou...

PCCTC investigator Michael A. Carducci, MD discusses consensus recommendations for PARP inhibitor use in metastatic prostate cancer with Alan Bryce, MD via UroToday: www.urotoday.com/video-lectur...

Learn more about the PCCTC-managed PROMISE, a registry of prostate cancer patients participating in a research study to learn how genetic differences can affect patient outcomes: www.prostatecancerpromise.org

Esteemed PCCTC investigator Dr Rana McKay discusses the exciting developments in biomarker-driven therapy for metastatic castration-sensitive prostate cancer via @onclive.bsky.social: www.onclive.com/view/emergin...

Mark Your Calendar! 🙌🏾🙌🏽🙌🏿 We’re headed to Lagos for the IRONMAN Conference from September 2nd through the 5th. This isn’t just an event, it’s a major milestone in global health and cancer research you won’t want to miss! Register now: surveys.mayoclinic.org/jfe/form/SV_...

PCCTC investigator Dr Rana McKay and colleagues discuss personalizing treatment intensification in metastatic castration-sensitive prostate cancer via @onclive.bsky.social: www.onclive.com/view/persona...

Just published: Analysis from the TRANSFORMER prostate cancer study reveals baseline testosterone could be considered in the treatment selection process when bipolar androgen therapy is an option www.nature.com/articles/s41...

From PCCTC investigator Dr Rana McKay and colleagues, "Radium-223 in Men with Metastatic Castration-resistant Prostate Cancer: A Systematic Literature Review of Real-world Outcomes in Observational Studies," published in Eur Urol Oncol www.sciencedirect.com/science/arti...

Prognostic Significance of PSA>0.2 After 6-12 Months Treatment for Metastatic Hormone-Sensitive Prostate Cancer Intensified by Androgen-Receptor Pathway Inhibitors: A Multinational Real-World Analysis of the PCCTC-managed IRONMAN Registry www.urotoday.com/conference-h...

Learn more about TALENT, the PCCTC-managed study of talazoparib with or without enzalutamide in people with #prostatecancer who have previously received abiraterone (NCT06844383): www.pcctc.org/talent

#ASCO25: PCCTC investigator Dr Rana McKay discusses the COMRADE study, "The combination of olaparib with radium-223 demonstrated feasibility, safety, and antitumor activity in patients with metastatic castration-resistant #prostatecancer with bone metastases”

PCCTC study of a novel CTLA-engaging IO plus Lu177-PSA-617 therapy in patients with metastatic castration-resistant #prostatecancer (mCRPC) at #ASCO25 #MedIQASCO25 with @tiansterzhangmd.bsky.social. Clear activity and safe!

Join us tomorrow (Tuesday) at #ASCO25 as PCCTC investigators present at the prostate cancer oral abstract session (Hall D1 and Live Stream)!

#ASCO25: PCCTC investigators Drs Karen Autio, Michael Schweizer, and Mark Stein contribute to first-in-human results for novel T-cell engager pasritamig (JNJ-78278343), showing early anti-tumor activity in #prostatecancer www.jnj.com/media-center...

The PCCTC at #ASCO25 via UroToday: A Randomized, Open-Label, Phase 2b Study of the Bromodomain Inhibitor ZEN-3694 + Enzalutamide vs Enzalutamide in Patients with mCRPC www.urotoday.com/conference-h...

Today at #ASCO25, Rapid Oral Sessions featuring PCCTC #prostatecancer science: the phase 2 Metacure trial, the novel B7H3 ADC DB‑1311/BNT324, and the phase 1 study results of JNJ-78278343

Mark Your Calendar! 📆 We’re headed to Lagos for the IRONMAN Conference from September 2nd through the 5th. This isn’t just an event, it’s a major milestone in global health and cancer research you won’t want to miss! Register now: surveys.mayoclinic.org/jfe/form/SV_...

DOD prostate cancer research program FY25 funding opportunities https://cancerletter.com/funding-opportunities/20250523_10a/

#ASCO25 is just days away. Be sure to check out the innovative PCCTC prostate cancer clinical research presented at this year's annual meeting in Chicago!

We are excited to announce science from innovative PCCTC multi-center prostate cancer studies will be represented by 16 abstracts at #ASCO25!

At MSK, there are exciting new therapies that are proving effective at treating metastatic prostate cancer. In this 📹, Dr. Michael Morris, a genitourinary medical oncologist and the Prostate Cancer Section Head at MSK, speaks about one in particular. Plus, read more here: bit.ly/4mfOKhg

The PCCTC's Dr. Michael J. Morris and other experts weigh in on President Biden's prostate cancer diagnosis and the debate about prostate screenings for older men: www.washingtonpost.com/health/2025/...

We’re headed to Lagos for the IRONMAN Conference from September 4–6, with a special pre-conference session on September 3. This isn’t just an event—it’s a major milestone in global health and cancer research you won’t want to miss! Register now: surveys.mayoclinic.org/jfe/form/SV_...

Just published: PCCTC study of Olaparib and Durvalumab in Patients with DNA Damage Repair Alterations and Biochemically Recurrent Prostate Cancer by Dr Karen A Autio and colleagues: pmc.ncbi.nlm.nih.gov/articles/PMC...